Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 24;8:1491. doi: 10.1038/s41598-018-19473-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Plasma levels of VEGF-A, VWF antigen, and ADAMTS13 activity in patients with untreated exudative AMD and controls. (A) Plasma levels of VEGF-A in patients with AMD were significantly lower than those in controls (**p < 0.01). The minimum detectable dose (MDD) of VEGF-A defined by the manufacturer was 9 pg/ml. (B) Plasma levels of VWF antigen (:Ag) in patients with age-related macular degeneration (AMD) were significantly higher than those in controls (***p < 0.001). (C) Plasma ADAMTS13 activity (:AC) levels in patients with AMD were almost the same as those in controls.